Key Takeaways BHC posted Q2 EPS of $0.90, missing estimates, while revenues rose 5% to $2.53B, beating forecasts.Salix revenues grew 12% to $627M, driven by higher demand for Xifaxan, Trulance, and Relistor.BHC is set to acquire DRRX for $63M, along with milestone payments. Shares of Bausch Health Companies Inc. ((BHC) declined 6.3% after the company reported mixed results for the second quarter of 2025.Adjusted earnings per share of 90 cents missed the Zacks Consensus Estimate of 97 cents. The earnings wer ...

Bausch Health Companies Inc. BHC on Tuesday agreed to indirectly acquire DURECT Corp DRRX, including a novel therapeutic molecule, larsucosterol.Larsucosterol, an endogenous sulfated oxysterol and an epigenetic modulator, has demonstrated promising results for alcoholic hepatitis (AH) in Phase 2 trials.Alcoholic hepatitis is a severe liver inflammation caused by excessive alcohol consumption. It is characterized by the rapid onset of jaundice and liver enlargement.Bausch Health’s hepatology development and ...